Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment

被引:101
作者
Beam, Elena [1 ]
Razonable, Raymund R. [1 ,2 ,3 ]
机构
[1] Mayo Clin, Coll Med, Dept Med, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Div Infect Dis, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, William J von Liebig Transplant Ctr, Rochester, MN 55905 USA
关键词
Cytomegalovirus; Solid organ transplant; Epidemiology; Immunologic monitoring; Antiviral prophylaxis; Preemptive therapy; Prevention strategies; EXTENDED VALGANCICLOVIR PROPHYLAXIS; CLINICAL UTILITY; DISEASE; RISK; RECIPIENTS; INFECTION; GANCICLOVIR; EFFICACY; SAFETY; ASSAY;
D O I
10.1007/s11908-012-0292-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Cytomegalovirus (CMV) is one of the most important pathogens that infect solid organ transplant recipients. CMV is associated with increased morbidity and mortality in this population as a result of its numerous direct and indirect effects. Prevention strategies consist of preemptive therapy and antiviral prophylaxis, and the choice of which preventive approach to implement should be guided by advantages and drawbacks related to the population being managed. There are differences in the approaches to the laboratory diagnosis and treatment of CMV infection and disease depending on assay availability, clinical presentation, disease severity, and specific transplant populations. In this article, the authors aim to summarize recent publications and updates in the epidemiology, diagnosis, prevention, and treatment of CMV infection in solid organ transplant recipients during the past year, including a brief review of future directions in the field.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 39 条
[1]   Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients [J].
Angeles Clari, Maria ;
Munoz-Cobo, Beatriz ;
Solano, Carlos ;
Benet, Isabel ;
Costa, Elisa ;
Jose Remigia, Maria ;
Bravo, Dayana ;
Amat, Paula ;
Navarro, David .
CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (05) :791-796
[2]   Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients [J].
Asberg, A. ;
Humar, A. ;
Rollag, H. ;
Jardine, A. G. ;
Mouas, H. ;
Pescovitz, M. D. ;
Sgarabotto, D. ;
Tuncer, M. ;
Noronha, I. L. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) :2106-2113
[3]   Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis [J].
Boivin, Guy ;
Goyette, Nathalie ;
Farhan, Mahdi ;
Ives, Jane ;
Elston, Robert .
JOURNAL OF CLINICAL VIROLOGY, 2012, 53 (03) :208-213
[4]   Association of Cytomegalovirus Infection and Disease With Death and Graft Loss After Liver Transplant in High-Risk Recipients [J].
Bosch, W. ;
Heckman, M. G. ;
Diehl, N. N. ;
Shalev, J. A. ;
Pungpapong, S. ;
Hellinger, W. C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (10) :2181-2189
[5]   Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis [J].
Boudreault, A. A. ;
Xie, H. ;
Rakita, R. M. ;
Scott, J. D. ;
Davis, C. L. ;
Boeckh, M. ;
Limaye, A. P. .
TRANSPLANT INFECTIOUS DISEASE, 2011, 13 (03) :244-249
[6]  
Brennan D C, 2011, Am J Transplant, V11, P2453, DOI 10.1111/j.1600-6143.2011.03674.x
[7]   Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial [J].
Copeland, C. Ashley Finlen ;
Davis, W. Austin ;
Snyder, Laurie D. ;
Banks, Missy ;
Avery, Robin ;
Davis, R. Duane ;
Palmer, Scott M. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (09) :990-996
[8]   Cytomegalovirus Disease in Kidney Transplant Recipients: Incidence, Clinical Profile, and Risk Factors [J].
Cordero, E. ;
Casasola, C. ;
Ecarma, R. ;
Danguilan, R. .
TRANSPLANTATION PROCEEDINGS, 2012, 44 (03) :694-700
[9]   Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa) [J].
Couzi, Lionel ;
Pitard, Vincent ;
Sicard, Xavier ;
Garrigue, Isabelle ;
Hawchar, Omar ;
Merville, Pierre ;
Moreau, Jean-Francois ;
Dechanet-Merville, Julie .
BLOOD, 2012, 119 (06) :1418-1427
[10]   QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity [J].
Giulieri, Stefano ;
Manuel, Oriol .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2011, 11 (01) :17-25